Literature DB >> 7586256

Exercise capacity in hypertrophic cardiomyopathy. Role of stroke volume limitation, heart rate, and diastolic filling characteristics.

S S Lele1, H L Thomson, H Seo, I Belenkie, W J McKenna, M P Frenneaux.   

Abstract

BACKGROUND: We previously showed that exercise capacity in patients with hypertrophic cardiomyopathy (HCM) is related to peak exercise cardiac output. Cardiac output augmentation during exercise is normally dependent on heart rate (HR) response and stroke volume (SV) augmentation by increased left ventricular end-diastolic volume and/or increased contractility. We hypothesized that in contrast to normal subjects, peak exercise capacity in patients with HCM is determined by the diastolic filling characteristics of the left ventricle during exercise, which would in turn determine the degree to which SV is augmented, and that HR is a relatively unimportant determinant of peak exercise capacity. METHODS AND
RESULTS: Twenty-three patients with HCM underwent invasive hemodynamic evaluation and measurement of maximal oxygen consumption (VO2max) during erect treadmill exercise to assess the relative importance of changes in HR and SV in determining exercise capacity. Hemodynamic responses to erect and supine exercise were compared in 10 of these patients. In a separate group of 46 patients with HCM, the relation between VO2max and exercise diastolic filling indexes was assessed. Peak HR during erect exercise was 92 +/- 8% of predicted maximum. VO2max was 29.0 +/- 6.4 mL.kg-1.min-1 and was related significantly to peak exercise cardiac index and SV index (r = .71, P < .001 and r = .66, P = .001, respectively) but not to peak HR, HR deficit, or resting or peak pulmonary capillary wedge pressure. Peak cardiac output during erect exercise was not related to peak HR (r = .13, P = NS). When erect and supine exercise were compared, peak HR was lower in the supine position (153.3 +/- 19.9 beats per minute supine versus 172.0 +/- 17.6 beats per minute erect, P = .003), but peak exercise cardiac index was similar (7.9 +/- 2.6 L.min-1.m-2 supine versus 7.5 +/- 2.8 L.min-1.m-2 erect). Pulmonary capillary wedge pressure was higher at rest in the supine versus erect position (15.3 +/- 5.2 versus 8.1 +/- 6.1 mm Hg) but was not significantly higher at peak exercise in the supine versus erect position (28.5 +/- 8 versus 22.4 +/- 11.6 mm Hg erect, P = NS). In the separate group of 46 patients with HCM, VO2max was significantly inversely related to time to peak filling at peak exercise (r = -.60, P < .0001) but did not correlate with time to peak filling at rest, resting ejection fraction, peak filling rate, or peak exercise peak filling rate.
CONCLUSIONS: SV is the major determinant of peak exercise capacity in the erect position in patients with hypertrophic cardiomyopathy. This in turn is determined by the exercise left ventricular diastolic filling characteristics. HR augmentation does not appear to be a major determinant of peak cardiac output in the erect position.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586256     DOI: 10.1161/01.cir.92.10.2886

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  38 in total

Review 1.  Echocardiographic differentiation of pathological and physiological left ventricular hypertrophy.

Authors:  D J Hildick-Smith; L M Shapiro
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 2.  Medical treatment of hypertrophic cardiomyopathy.

Authors:  M V Sherrid; D Gunsburg; A Sharma
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

3.  Exercise in hypertrophic cardiomyopathy.

Authors:  Sharlene M Day
Journal:  J Cardiovasc Transl Res       Date:  2009-10-14       Impact factor: 4.132

4.  Clinical significance of N-terminal-probrain natriuretic peptide in hypertrophic cardiomyopathy.

Authors:  Georgios K Efthimiadis; Areti Hitoglou-Makedou; Georgios Giannakoulas; Anastasia Mitakidou; Theodoros Karamitsos; Haralambos Karvounis; Sotirios Mochlas; Ioannis Styliadis; Haris Stefanidis; Georgios Parcharidis; Georgios Louridas
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

5.  Genes, geography and geometry: the "critical mass" in hypertrophic cardiomyopathy.

Authors:  Nina Kaludercic; Carlo Reggiani; Nazareno Paolocci
Journal:  J Mol Diagn       Date:  2008-12-04       Impact factor: 5.568

6.  Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure.

Authors:  Kurt R Daniel; Gretchen Wells; Kathryn Stewart; Brian Moore; Dalane W Kitzman
Journal:  Congest Heart Fail       Date:  2009 Mar-Apr

7.  Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve.

Authors:  Gunnar Plehn; Julia Vormbrock; Axel Meissner; Hans-Joachim Trappe
Journal:  J Nucl Cardiol       Date:  2009-01-22       Impact factor: 5.952

8.  Early diastolic function during exertion influences exercise intolerance in patients with hypertrophic cardiomyopathy.

Authors:  Kei Mizukoshi; Kengo Suzuki; Kihei Yoneyama; Ryo Kamijima; Seisyou Kou; Manabu Takai; Masaki Izumo; Akio Hayashi; Eiji Ohtaki; Yoshihiro J Akashi; Naohiko Osada; Kazuto Omiya; Tomoo Harada; Sachihiko Nobuoka; Fumihiko Miyake
Journal:  J Echocardiogr       Date:  2012-10-19

9.  The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.

Authors:  Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

10.  Relationship between serum biochemical markers of myocardial fibrosis and diastolic function at rest and with exercise in hypertrophic cardiomyopathy.

Authors:  Chi Young Shim; Jong-Won Ha; Eui-Young Choi; Hyun-Jin Lee; Sun-Ha Moon; Jin-Mi Kim; Se-Joong Rim; Namsik Chung
Journal:  Korean Circ J       Date:  2009-12-30       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.